At first glance Obamacare developments for the American Rx industry in 2015 appear fairly benign. However, digging deeper suggests that each, in its own way, could cause various actions with potential for substantial uncertainty for the U.S. pharmaceutical industry next year. If your response to this profound observation was, “Really, what’s new?” — read on. Read More »
2014 marked the 80th anniversary of Laboratorios Bagó, a market leader in Argentina and also Latin America, with products in in 47 countries. In this interview with Pharmaboardroom.com, Juan Pablo Bagó, general director of pharma in Argentina for the Bagó group, discusses the state of R&D in Argentina, and explains why his group is planning for a 75 percent of turnover from international markets in the coming years.
Indonesia is expected to be the most promising market for pharma next year, thanks to its new healthcare insurance scheme Jaminan Kesehatan Nasional (JKN), according to Reenita Das, partner and senior vice president of Healthcare & Life Sciences at Frost & Sullivan.Read More »
More new medicines came to market in 2013, and fewer blockbuster drugs lost patent protection, trends that federal analysts say led to more rapid growth in outlays for prescription drugs in 2013. Retail prescription drug spending rose 2.5% to reach $271 billion a year ago, much faster than the low growth rate of 0.5% in 2013, according to the annual report on national health spending from the Centers for Medicare & Medicaid Services (CMS), published by Health Affairs. Read More »